Lyell Immunopharma (LYEL) Cash from Operations (2020 - 2026)
Lyell Immunopharma recorded quarterly Cash from Operations of 38510000.0 in Q1 2026, down 19.41% quarter-over-quarter from 32251000.0 in Q4 2025, and up 29.65% year-over-year from 29703807.18 in Q1 2025.
Lyell Immunopharma's Cash from Operations history runs 7 years deep, the most recent figure standing at 38510000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 29.65% year-over-year to 38510000.0; the TTM figure through Mar 2026 stood at 133796000.0 (up 23.6% YoY), while the FY2025 annual figure was 150024000.0, up 7.62% from the prior year.
- Cash from Operations came in at 38510000.0 for Q1 2026 at Lyell Immunopharma, down from 32251000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 28577000.0 in Q3 2025 to a low of 54738000.0 in Q1 2025.
- A 5-year average of 40245705.88 and a median of 39161000.0 in 2023 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations plunged 45.55% in 2022 and soared 31.73% in 2025, its largest moves.
- Lyell Immunopharma's Cash from Operations stood at 40267000.0 in 2022, then dropped by 0.91% to 40635000.0 in 2023, then slipped by 16.26% to 47242000.0 in 2024, then jumped by 31.73% to 32251000.0 in 2025, then retreated by 19.41% to 38510000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 38510000.0, 32251000.0, and 28577000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Lyell Immunopharma | 373.31 Mn | 373.31 Mn | - | -38.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.51 Mn |
| Mar 31, 2026 | -38.51 Mn |
| Dec 31, 2025 | -32.25 Mn |
| Dec 31, 2025 | -32.25 Mn |
| Sep 30, 2025 | -28.58 Mn |
| Sep 30, 2025 | -28.58 Mn |
| Jun 30, 2025 | -34.46 Mn |
| Jun 30, 2025 | -34.46 Mn |
| Mar 31, 2025 | -54.74 Mn |
| Mar 31, 2025 | -54.74 Mn |
| Dec 31, 2024 | -47.24 Mn |
| Dec 31, 2024 | -47.24 Mn |
| Sep 30, 2024 | -35.04 Mn |
| Sep 30, 2024 | -35.04 Mn |
| Jun 30, 2024 | -38.09 Mn |
| Jun 30, 2024 | -38.09 Mn |
| Mar 31, 2024 | -42.02 Mn |
| Mar 31, 2024 | -42.02 Mn |
| Dec 31, 2023 | -40.64 Mn |
| Dec 31, 2023 | -40.64 Mn |
| Sep 30, 2023 | -37.69 Mn |
| Sep 30, 2023 | -37.69 Mn |
| Jun 30, 2023 | -39.16 Mn |
| Jun 30, 2023 | -39.16 Mn |
| Mar 31, 2023 | -46.21 Mn |
| Mar 31, 2023 | -46.21 Mn |
| Dec 31, 2022 | -40.27 Mn |
| Dec 31, 2022 | -40.27 Mn |
| Sep 30, 2022 | -37.10 Mn |
| Sep 30, 2022 | -37.10 Mn |
| Jun 30, 2022 | -44.33 Mn |
| Jun 30, 2022 | -44.33 Mn |
| Mar 31, 2022 | -47.85 Mn |
| Mar 31, 2022 | -47.85 Mn |
| Dec 31, 2021 | -33.21 Mn |
| Dec 31, 2021 | -33.21 Mn |
| Sep 30, 2021 | -25.49 Mn |
| Sep 30, 2021 | -25.49 Mn |
| Jun 30, 2021 | -33.95 Mn |
| Jun 30, 2021 | -33.95 Mn |
| Mar 31, 2021 | -33.60 Mn |
| Mar 31, 2021 | -33.60 Mn |
| Dec 31, 2020 | -26.73 Mn |
| Dec 31, 2020 | -26.73 Mn |
| Sep 30, 2020 | -21.63 Mn |
| Sep 30, 2020 | -21.63 Mn |